How Electronic Patient-Reported Outcomes (ePRO) Support Clinical Trials
Source: EClinCloud. Author: EClinCloud.
//
Patient-reported outcomes (PROs) are an important way to increase patient participation in diagnosis and treatment under the new medical model1. According to the FDA, a PRO refers to a report on health status that comes directly from the patient—a subjective evaluation of the patient's own health status without amendment or interpretation by a clinician or anyone else2. The approach of using electronic methods to record PROs is known as electronic patient-reported outcomes (ePRO).
ePRO collects data in a variety of formats, including scales, questionnaires, patient diaries, patient interviews, and wearable devices, among others3.
ePRO can assess multiple dimensions of a patient's health status1,4:
Health-Related Quality of Life (HRQoL): HRQoL represents a patient's overall health status based on their perception of physical, psychological, and social functioning. It encompasses three elements—multidimensionality, subjectivity, and variability—and is an important indicator for evaluating patient treatment outcomes.
Patient functional status: refers to a patient's ability to perform activities of daily living, including physical function, cognitive function, and sexual function, among others.
Disease symptoms and symptom burden: Symptoms are subjective evidence of a disease, health condition, or treatment-related outcome that can be recognized by the patient, including both disease-related symptoms and treatment-related symptoms. Symptoms can be evaluated in terms of severity, trends over time, and their impact on patient function.
Health behaviors: Behaviors that affect disease and health, such as smoking, excessive alcohol consumption, and an unhealthy diet. These behaviors may increase disease risk or affect patient compliance.
Patient evaluations: Patient evaluations mainly cover three aspects—satisfaction with medical services, satisfaction with the treatment regimen, and satisfaction with the medication itself. They are an important component of "patient-centered" clinical research.
Data collected through ePRO can help investigators assess drug efficacy and side effects, patient symptoms, function, and quality of life, protocol compliance, and tolerability of toxicity5.
Compared with paper PROs, ePRO has 2 main advantages5:
1
Data are traceable with clear timestamps
2
Data can be obtained in real time
In clinical studies, these advantages specifically manifest as follows5,6:
1
1. Patients can report using convenient devices such as mobile phones, reducing patient burden and increasing patient compliance
2
Patients can report adverse events and their severity in real time, which increases data accuracy and improves data quality compared with reporting after long intervals
3
When a patient experiences an adverse event, the investigator can receive timely alerts and manage it, enhancing physician-patient communication
4
The ePRO system allows patients to complete assessments within specified time windows, reducing investigator burden and increasing clinical visit efficiency. For example, patients can complete assessments within a scheduled time before a visit, enabling the investigator to quickly identify key symptoms and disease progression requiring attention during the visit and provide targeted feedback and management
5
It can help investigators systematically collect the data of interest to them
6
It enables the establishment and implementation of standardized PRO methods in clinical studies
In addition, the ePRO system can include an online patient training and education function to strengthen patients' understanding of their disease and standardize the completion and use of scales.
The growing use of ePRO in clinical studies in recent years reflects the recognition that patients themselves are the best source of information for describing their disease. Investigators have also recognized that, compared with paper data, ePRO enables more accurate and convenient data collection. Based on higher-quality data, investigators can also provide more effective treatment approaches; moreover, regulatory authorities have greater confidence in the data, and sponsors can better plan the development of new drugs5.
References
1. Jiang Qian. Patient-reported outcomes and their application in hematologic malignancies. Chinese Journal of Hematology (中华血液学杂志), 2019,40 (7): 614-619. DOI: 10.3760/cma.j.issn.0253-2727.2019.07.019
2. FDA. https://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions
3. Li Xiaoxian, Zhao Ye, Lin Feng, et al. Application of Electronic Patient-Reported Outcomes in Efficacy Evaluation of New Drug Clinical Trials. Drug Evaluation Research, 2021.
4. Cella, David, et al. Patient-Reported Outcomes in Performance Measurement. RTI Press, September 2015. doi:10.3768/rtipress.2015.bk.0014.1509
5. ACT. https://www.appliedclinicaltrialsonline.com/view/epro-supports-patients-clinicians-regulators-and-industry-oncology
6. Bennett, Antonia V et al. "Electronic patient-reported outcome systems in oncology clinical practice." CA: a cancer journal for clinicians vol. 62,5 (2012): 337-47. doi:10.3322/caac.21150
About EClinCloud
EClinCloud provides an integrated, all-in-one cloud platform (including solutions such as CTMS, eTMF, EDC, RTSM, eCOA, and eConsent, and consulting services including scale management, linguistic validation, rater training, study build and configuration, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including oncology, neurology, cardiology, pulmonology, dermatology, and others). By combining cutting-edge technology with life data to build a globally leading, "patient-centric" SaaS cloud platform for clinical evidence support, it helps domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.



